1.50

7.14% 0.10

Pre-market: 1.53 0.03 +2.00%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.50, with a volume of 3.27M. It is up +7.14% in the last 24 hours and up +8.70% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$1.40

Open:

$1.41

24h Volume:

3.27M

Relative Volume:

1.11

Market Cap:

$402.38M

Revenue:

$236.20M

Net Income/Loss:

$-5.35M

P/E Ratio:

-83.80

EPS:

-0.0179

Net Cash Flow:

$67.70M

1W Performance:

+5.63%

1M Performance:

+8.70%

6M Performance:

-28.23%

1Y Performance:

-38.78%

1-Day Range:

$1.41

$1.53

1-Week Range:

$1.35

$1.53

52-Week Range:

$1.14

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1111)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2026-05-14

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	1.50	402.38M	236.20M	-5.35M	67.70M	-0.0179
TAK Takeda Pharmaceutical Co Adr	16.56	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.68	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.35	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.24	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	581.22	24.67B	3.18B	1.33B	1.04B	27.90

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

May 04, 2026

Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan

May 04, 2026

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 04, 2026

Akebia Therapeutics Announces Vadadustat Post-hoc Win - GlobeNewswire

May 04, 2026

May 02, 2026

MSN Money - MSN

May 02, 2026

May 01, 2026

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights - Moomoo

May 01, 2026

Akebia Therapeutics (NASDAQ:AKBA) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

May 01, 2026

Earnings Preview: AKBA to Report Financial Results Pre-market on May 07 - Moomoo

May 01, 2026

Apr 30, 2026

Are options traders betting on a big move in Akebia Therapeutics stock? - MSN

Apr 30, 2026

Apr 28, 2026

Akebia (NASDAQ: AKBA) plans major increase in authorized common shares - Stock Titan

Apr 28, 2026

Apr 24, 2026

Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson & Johnson, Roche, Biocon Biologics - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Apr 23, 2026

Akebia (AKBA) Road Ahead | Q4 2025: EPS Misses ViewsCertified Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 20, 2026

Akebia (AKBA) Stock: Long-Term Outlook Review (Steady Climb) 2026-04-20Verified Analyst Reports - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 20, 2026

Apr 18, 2026

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023 - GuruFocus

Apr 18, 2026

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN

Apr 18, 2026

Apr 17, 2026